A case series of comorbidities seen in bullous pemphigoid
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20243876Keywords:
Bullous pemphigoid, Omalizumab, ComorbiditiesAbstract
Bullous pemphigoid (BP) is an autoimmune skin blistering disease commonly seen in the elderly which is associated with increased morbidity. The association of BP with comorbidities, especially cardiovascular, neurological, type 2 diabetes mellitus (T2DM) and has been seeing a rising trend in the recent years, not only with the underlying condition but also the drugs associated. A systematic literature review was conducted to identify and analyze the comorbidities prevalent in patients with BP.
Metrics
References
Kibsgaard L, Bay B, Deleuran M, Vestergaard C. A retrospective consecutive case-series study on the effffect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre. Acta Derm Venereol. 2015;95(3):307-11. DOI: https://doi.org/10.2340/00015555-1925
Beissert S, Werfel T, Frieling U, Böhm M, Sticherling M, Stadler R, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143(12):1536-42. DOI: https://doi.org/10.1001/archderm.143.12.1536
Försti AK, Huilaja L, Schmidt E, Tasanen K. Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol. 2017;26(12):1228-34. DOI: https://doi.org/10.1111/exd.13401
Sticherling M, Franke A, Aberer E, Gläser R, Hertl M, Pfeiffffer C, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol. 2017;177(5):1299-305. DOI: https://doi.org/10.1111/bjd.15649
Russo R, Cozzani E, Gasparini G, Parodi A. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases? Dermatol Ther. 2020;33(1);e13190. DOI: https://doi.org/10.1111/dth.13190
Bech R, Kibsgaard L, Vestergaard C. Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature. Front Med (Lausanne). 2018;5:238. DOI: https://doi.org/10.3389/fmed.2018.00238
Silverii GA, Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine. 2020;69(3):504-7. DOI: https://doi.org/10.1007/s12020-020-02272-x
Cao P, Xu W, Zhang L. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review. Front Immunol. 2022;13:928621. DOI: https://doi.org/10.3389/fimmu.2022.928621
Gambichler T, Segert H, Höxtermann S, Schmitz L, Altmeyer P, Teegen B. Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations. J Eur Acad Dermatol Venereol. 2015;29(9):1758-62. DOI: https://doi.org/10.1111/jdv.12995
Lucariello RJ, Villablanca SE, Mascaró JM Jr, Reichel M. Association between bullous pemphigoid and malignancy: A meta-analysis. Australas J Dermatol. 2018;59(4):253-60. DOI: https://doi.org/10.1111/ajd.12764
Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389:1630-8. DOI: https://doi.org/10.1016/S0140-6736(17)30560-3
Downloads
Published
How to Cite
Issue
Section
